Compare Kroger Co (KR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Medpace Holdings Inc — how do they compare? Kroger Co trades at $57.72 (market cap $35.75B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Kroger Co is far larger — about 2.4× Medpace Holdings Inc's market cap, and Kroger Co pays a 2.47% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| KR | MEDP | |
|---|---|---|
Market Cap | $35.75B | $15.08B |
Sector | Consumer Staples | Technology |
52-Week High | $75.60 | $620.59 |
52-Week Low | $55.53 | $308.88 |
Enterprise Value | $55.85B | $14.55B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $57.78, down 1.77% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a low P/S ratio of 0.25 and improving cash flow, generating $2.08B net cash in 2025. Recent developments include the $1.65B Giant Eagle acquisition expanding Midwest presence and ongoing dividend payments, with analyst consensus pointing to 19% upside to the $68.63 price target.
KR presents a value opportunity with defensive characteristics, trading below analyst targets amid competitive grocery sector pressures. Key risks include margin compression from industry pricing wars and integration challenges from recent acquisitions, while positive catalysts include retail media growth and private label expansion driving long-term shareholder value.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
